FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

Conditions:   Gastro-Esophageal Junction Adenocarcinoma;   Gastric Cancer
Interventions:   Drug: Nab-paclitaxel 150 mg/m^2;   Drug: Oxaliplatin 85 mg/m^2;   Drug: 5-FU 1200 mg/m^2 x 2 D;   Drug: Leucovorin 400 mg/m^2
Sponsors:   Al B. Benson, III, MD;   Celgene Corporation;   Big Ten Cancer Research Consortium
Not yet recruiting - verified September 2017

http://ift.tt/2y8mzZz